Inhibition of Caspase‐1 Suppresses GSDMD‐mediated Peritoneal Mesothelial Cell Pyroptosis and Inflammation in Peritoneal Fibrosis
Small · 2025-04 · 21 (14)
DOI: 10.1002/smll.202409362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 28.02.2025. Verfasst von Yingfeng Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. Hauptthemen laut MEDLINE: Pyroptosis, Caspase 1, Peritoneal Fibrosis, Phosphate-Binding Proteins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Scientific Committee of China, Key Discipline Construction Project of Shanghai Pudong New Area Health Commission.
Abstract (Originalsprache)
Pyroptosis, belonging to programmed cell death, is shown to be mediated by gasdermin D (GSDMD) and gains more and more attention in innate immunity and multiple diseases. However, the role of GSDMD‐mediated pyroptosis in peritoneal fibrosis (PF) remains unclear. This study observed NLRP3 inflammasome activation and pyroptosis in the peritoneum of long‐term peritoneal dialysis (PD) patients with PF. Moreover, it is found that high glucose (HG) can induce the activation of NLRP3 inflammasome by regulating TLR4/NF‐κB and JNK/p38 MAPK signaling in human peritoneal mesothelial cells (HPMCs), leading to subsequent Caspase‐1 activation. The cleaved Caspase‐1 promoted pyroptosis‐related transmembrane pore formation through activating GSDMD‐N, and stimulated the HPMCs to secrete inflammatory factors including IL‐1β and IL‐18. GSDMD global deletion or pharmacologic pretreatment with Caspase‐1 specific inhibitor VX‐765 effectively inhibited the pyroptosis and inflammation, thereby ameliorating PF. Additionally, treatment with VX‐765 and transfected with Caspase‐1 siRNA or GSDMD siRNA also inhibited the transmembrane pore formation and inflammatory factors secretion in HG‐induced HPMCs. Consistent with these results, delayed treatment with VX‐765 also alleviated PF, indicating the therapeutic effect of VX‐765. Taken together, the results demonstrate that pyroptosis may be a novel therapeutic target for peritoneal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
- Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, 02902, USA.
ORCID-Profile: Na Liu
Förderung
- National Natural Science Foundation of China
- Shanghai Scientific Committee of China
- Key Discipline Construction Project of Shanghai Pudong New Area Health Commission
- Discipline Construction Project of Shanghai Pudong New Area Health Commission
- Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai
- Shanghai Pudong New Area summit (emergency medicine and critical care) construction project
- Shanghai Sailing Program
- Clinical investigation grant of Shanghai East Hospital
Zitieren
APA
Shi, Y., Hu, Y., Li, J., Chen, H., Zhong, Q., Ma, X., Li, X., Zhang, S., Zhuang, S., & Liu, N. (2025). Inhibition of Caspase‐1 Suppresses GSDMD‐mediated Peritoneal Mesothelial Cell Pyroptosis and Inflammation in Peritoneal Fibrosis. Small, 21(14). https://doi.org/10.1002/smll.202409362
Vancouver
Shi Y, Hu Y, Li J, Chen H, Zhong Q, Ma X, et al. Inhibition of Caspase‐1 Suppresses GSDMD‐mediated Peritoneal Mesothelial Cell Pyroptosis and Inflammation in Peritoneal Fibrosis. Small. 2025;21(14). doi:10.1002/smll.202409362
BibTeX
@article{Shi2025,
author = {Shi, Yingfeng and Hu, Yan and Li, Jinqing and Chen, Hui and Zhong, Qin and Ma, Xiaoyan and Li, Xialin and Zhang, Shasha and Zhuang, Shougang and Liu, Na},
title = {Inhibition of Caspase‐1 Suppresses GSDMD‐mediated Peritoneal Mesothelial Cell Pyroptosis and Inflammation in Peritoneal Fibrosis},
journal = {Small},
year = {2025},
volume = {21},
number = {14},
doi = {10.1002/smll.202409362}
}
EUVIMED